Small-bowel transplantation is done infrequently (eg, < 200 transplants in the US in 2008). It is indicated for patients who
Procurement from a brain-dead, beating-heart donor is complex, partly because the small bowel can be transplanted alone, with a liver, or with a stomach, liver, duodenum, and pancreas. The role of living-related donation for small-bowel allografts has yet to be defined. Procedures vary by medical center; immunosuppressive regimens also vary, but a typical regimen includes antilymphocyte globulin for induction, followed by high-dose tacrolimus and mycophenolate mofetil for maintenance.
Weekly endoscopy is indicated to check for rejection. About 30 to 50% of recipients have one or more bouts of rejection within the first year after transplantation. Symptoms and signs of rejection include diarrhea, fever, and abdominal cramping. Endoscopic findings include mucosal erythema, friability, ulceration, and exfoliation; changes are distributed unevenly, may be difficult to detect, and can be differentiated from cytomegalovirus enteritis by viral inclusion bodies. Biopsy findings include blunted villi and inflammatory infiltrates in the lamina propria. Treatment of acute rejection is high-dose corticosteroids, antithymocyte globulin, or both.
Surgical complications affect 50% of patients and include anastomotic leaks, biliary leaks and strictures, hepatic artery thrombosis, and chylous ascites. Nonsurgical complications include graft ischemia and graft-vs-host disease caused by transplantation of gut-associated lymphoid tissue.
At 3 yr, survival rates after small-bowel transplantation alone are
Infections commonly contribute to death.
With liver and small-bowel transplantation, survival rates are lower because the procedure is more extensive and the recipient's condition is more serious. However, after the perioperative phase, graft and patient survival rates are higher than those after small-bowel transplantation alone, presumably because the transplanted liver has a protective effect, preventing rejection by absorbing and neutralizing antibodies.
Last full review/revision April 2013 by Martin Hertl, MD, PhD; Paul S. Russell, MD
Content last modified August 2013